Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Evotec Wins NIH Compound Contract
by Michael McCoy
September 24, 2012
| A version of this story appeared in
Volume 90, Issue 39
Evotec will expand its small-molecule compound management agreement with NIH under a new contract. Since 2004, the company’s Compound Focus subsidiary in South San Francisco has acquired, stored, and distributed compounds for NIH-supported high-throughput screening centers. The new contract extends the agreement for up to 10 years at a value of up to $75 million. In addition, the compounds will now be made available to select outside collaborators. Evotec says it plans to expand its compound management capabilities to the U.S. East Coast and Europe.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter